


# Stanford

---



## Meihsi Chen

Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine

### CLINICAL OFFICE (PRIMARY)

- **Anesthesia Department**

300 Pasteur Dr Rm H3580

MC 5640

Stanford, CA 94305

Tel (650) 723-5728      Fax (650) 725-8544

### Bio

---

#### CLINICAL FOCUS

- Anesthesia

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine

#### PROFESSIONAL EDUCATION

- Board Certification: Anesthesia, American Board of Anesthesiology (2023)
- Residency: Stanford University Anesthesiology Residency (2022) CA
- Internship: Stanford University Internal Medicine Residency (2018) CA
- Medical Education: Stanford School of Medicine (2017) CA
- M.D., Stanford University School of Medicine (2017)
- M.S., Stanford University School of Medicine , Epidemiology and Clinical Research (2017)
- B.S., University of Toronto , Laboratory Medicine and Pathobiology (2012)

### Publications

---

#### PUBLICATIONS

- **Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents** *BRITISH JOURNAL OF CANCER*  
Saha, M. N., Chen, Y., Chen, M., Chen, G., Chang, H.  
2014; 110 (9): 2224-2231
- **CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavourable acute myeloid leukemia.** *Leukemia research*  
Chen, M. H., Chang, H.  
2013; 37 (8): 861

- **CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia** *LEUKEMIA RESEARCH*  
Chen, M., Atenafu, E., Craddock, K. J., Brandwein, J., Chang, H.  
2013; 37 (2): 122-128
- **Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib** *HUMAN PATHOLOGY*  
Chen, M., Qi, C., Reece, D., Chang, H.  
2012; 43 (6): 858-864
- **p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*  
Chen, M., Qi, C. X., Saha, M. N., Chang, H.  
2012; 137 (2): 208-212